ROCKVILLE, Md., Feb. 12, 2019 /PRNewswire/ -- RegeneRx
Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on
tissue protection, repair and regeneration, announced today that ReGenTree, LLC, a joint venture between GtreeBNT and RegeneRx,
has executed an agreement with Ora, Inc., located in Andover, Massachusetts, for initiation of
ARISE-3 to study ReGenTree's new drug, RGN-259, a sterile, preservative-free eye drop for the treatment of dry eye syndrome.
ARISE-3 is a randomized double-masked, placebo-controlled phase 3 clinical trial that is based on the results of previous
clinical trials, ARISE-1 and ARISE-2.
According to ReGenTree officials, "A total of 700 patients will be enrolled in the trial and we expect the treatment will be
completed in the first half of 2020."
"We are pleased that ReGenTree has initiated ARISE-3 and look forward to moving RGN-259 through the FDA regulatory process,
via ReGenTree or a partner, and into the market as soon as possible to treat this common disorder," stated J.J. Finkelstein,
Chief Executive Officer.
About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)
RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T?4) and its constituent
fragments, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical
development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and has patents and patent applications covering its products in many countries
throughout the world.
RegeneRx, through its U.S. joint venture, ReGenTree LLC, completed patient enrollment and treatment in its second Phase 3
clinical trial (ARISE-2) in approximately 600 patients with dry eye syndrome and reported positive clinical results with no
safety issues. ReGenTree is also conducting a 46-patient Phase 3 clinical trial in patients with neurotrophic keratopathy
(NK). Additionally, RGN-259 is being developed in patients with dry eye syndrome in Asia
through RegeneRx's two Asian partnerships. RGN-259 has been designated an orphan drug in the U.S. for the treatment of NK.
RGN-352, the Company's T?4-based injectable formulation, is a Phase 2-ready drug candidate designed to be administered
systemically to prevent and repair cardiac damage resulting from heart attacks and central nervous system tissue disorders such
as peripheral neuropathy, multiple sclerosis and traumatic brain injuries such as stroke. It may also have applications in
patients with severe septic shock.
RGN-137, also designated an orphan drug in the U.S., is the Company's T?4-based dermal gel formulation that is being developed
for epidermolysis bullosa, a rare skin condition. The Company's licensee, GtreeBNT, is sponsoring a clinical trials in the U.S.
and Europe.
For additional information about RegeneRx please visit www.regenerx.com.
Forward-Looking Statements
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of
the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could
cause actual results to be materially different from historical results or from any future results expressed or implied by such
forward-looking statements. There can be no assurance that any current or future animal studies or clinical trials or joint
ventures will start on time, be completed within a projection time-frame, or result in future value or approved products. There
can also be no assurance that the Company or its licensees will apply for an NDA in the future or that if the Company or a
licensee applies for an NDA, that it will be accepted by the FDA and/or that the product candidate will be approved for marketing
in the U.S. or any other country. There can be no assurance that RegeneRx will be able to finance operations in the near future
or through the completion of clinical development of its products by its partners. Please view these and other risks
described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk
Factors" section of the annual report on Form 10-K for the year ended December 31, 2017, and
subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements
in this press release represent the Company's views only as of the date of this release and should not be relied upon as
representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this
information as a result of future events or otherwise, except as required by applicable law.
View original content:http://www.prnewswire.com/news-releases/regenerxs-us-joint-venture-initiates-key-phase-3-dry-eye-clinical-trial-with-rgn-259-300793999.html
SOURCE RegeneRx Biopharmaceuticals, Inc.